Related Experiment Video
Updated: Jun 29, 2025

12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
21.4K
In solid tumors, neoadjuvant or adjuvant immune checkpoint blockade increases treatment-related grade 3 or 4 adverse
1IEO, European Institute of Oncology IRCCS, Milan, Italy (L.B.).
Annals of Internal Medicine
|April 1, 2024
Abstract
Source Citation:
Fujiwara Y, Horita N, Adib E, et al. Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials. Lancet Oncol. 2024;25:62-75. 38012893.

